United StatesHealthcare and life sciences2025 – ongoingZoetis
Generative AI for study reports and regulatory dossiers
Zoetis said generative AI shortened regulatory approval timelines by months
Problem
Zoetis needed to prepare study reports and regulatory submissions as part of developing animal-health products. It sought shorter development timelines while maintaining document quality and compliance.
Approach
Zoetis used generative AI to automate study reports and regulatory dossiers within R&D. Its 2025 annual report described the application as operational and attributed shorter approval timelines to it. The company did not identify the models or explain the document-review workflow.
Results
No published figures
Takeaway
Zoetis claimed months saved but disclosed no project-level baseline or calculation method.
Categories
- Size
- Large enterprise
- Industry
- Healthcare and life sciences
- Business function
- IT and R&DFinance, risk and legal
- Innovation type
- Process innovation
- AI technology
- Generative AI
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
Zoetis described generative AI automating study reports and regulatory dossiers. It claimed improved quality and compliance and months saved in approval timelines, without publishing a numerical breakdown or comparison method.
Full details are in the original sources.